Topic: cardiovascular disease
Quantum Genomics’ blood pressure drug firibastat met its endpoints in a phase 2b study, paving the way for a wider trial in resistant hypertension.
Esperion has the 52-week safety data it needed for its cholesterol therapy bempedoic acid, clearing the way for regulatory filings next year.
Morphic Therapeutic brought in $80 million to carry its two lead integrin-targeting programs through their clinical proof-of-concept studies.
Akcea reported topline data showing its hyperlipoproteinemia drug lowered lipoprotein(a) levels in a phase 2 study in patients with cardiovascular disease.
An expanded understanding of the genetics behind breast cancer and blood pressure could improve treatments.
Saranas raised $2.8 million for a clinical pilot of its internal bleeding monitoring system, recently submitted for an FDA de novo classification.
Scripps researchers pinpointed a protein that can sense blood flow and prompt tiny blood vessels to dilate. It may be a target for drug development.
Inhaled sodium nitrite missed both primary and secondary objectives in heart failure patients with preserved ejection fraction.
The collaboration will leverage BC’s technology and Finnish health records to better understand atrial fibrillation patients.
Van Alphen joins Inositec as the biotech gears up to move its lead vascular calcification candidate into the clinic next year.